Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jo Ann Szylit

Dermatology Kinnelon, NJ Medical Doctor

NPI 1134102106 CMS profile 51124

135 Kinnelon Rd, Suite 103, Kinnelon, NJ 07405

Open in the dashboard

General payments

$4,776

300 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jo Ann Szylit of Kinnelon, NJ is reported in the CMS Open Payments database as having received $4,776 across 300 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,084 63
2024 General $705 44
2023 General $512 30
2022 General $783 47
2021 General $557 38
2020 General $432 28
2019 General $703 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jo Ann Szylit
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Jo Ann Szylit were reported at $1,084. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Jo Ann Szylit Dermatology median Middle half National median
2019 $703 $454 $129–$1,240 $163
2020 $432 $235 $81–$756 $114
2021 $557 $377 $108–$1,108 $132
2022 $783 $514 $143–$1,391 $149
2023 $512 $607 $159–$1,674 $160
2024 $705 $751 $204–$1,903 $164
2025 $1,084 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $866 69 payments
  2. Novartis Pharmaceuticals Corporation $496 22 payments
  3. Janssen Biotech, Inc. $367 13 payments
  4. Sun Pharmaceutical Industries Inc. $365 19 payments
  5. Galderma Laboratories, L.P. $343 24 payments
  6. Regeneron Healthcare Solutions, Inc. $327 21 payments
  7. Pfizer Inc. $306 20 payments
  8. Amgen Inc. $255 17 payments
  9. Lilly USA, LLC $234 16 payments
  10. Genentech USA, Inc. $181 13 payments
  11. Other $1,037 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,477 296 payments
  2. Education $298 4 payments
Products named General payments · program years 2019–2025
  1. EUCRISA $277 19 payments
  2. DUPIXENT Inflammation And Immunology $276 18 payments
  3. SKYRIZI Immunology $263 24 payments
  4. Otezla $255 17 payments
  5. TREMFYA $251 5 payments
  6. TALTZ $234 16 payments
  7. RINVOQ $228 21 payments
  8. SKYRIZI Immunology $216 22 payments
  9. COSENTYX $186 9 payments
  10. DUPIXENT Immunology $168 9 payments
  11. Other $3,557 228 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,066

Median for Dermatology: 534

Drug cost

$286,436

Median for Dermatology: $67,151

Branded share of claims

12%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 27 $130,105
Humira Pen Adalimumab Brand 13 $88,550
Dupixent Pen Dupilumab Brand 13 $48,839
Fluocinonide Generic 98 $2,821
Fluorouracil Generic 47 $2,702
Ketoconazole Generic 116 $2,257
Clobetasol Propionate Generic 49 $1,712
Metronidazole Generic 53 $1,551
Triamcinolone Acetonide Generic 206 $1,428
Mometasone Furoate Generic 60 $1,273

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$376,403

Of which drugs: $12,294

Medicare patients

2,042

Average age 75

Services billed

5,663

1,238 women, 804 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Ischemic heart disease 26%
Diabetes 22%
Osteoporosis 20%
Cancer 17%
Atrial fibrillation 16%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 37 40 $12,294

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $75
  • Regeneron Healthcare Solutions, Inc. $65
$140 13 —
SKYRIZI
  • AbbVie, Inc. $112
$112 — —
TREMFYA
  • Janssen Biotech, Inc. $95
$95 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $86
$86 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record